Dr. Sacco on Upfront Treatments for Head and Neck Cancer

Assuntina G. Sacco, MD
Published: Friday, Nov 03, 2017



Assuntina G. Sacco, MD, assistant professor of medicine, medical oncologist, UC San Diego Health, discusses upfront treatment for patients with head and neck cancer.

Data suggests that higher-dose cisplatin is superior to weekly-dose regarding local regional control. There is a trend to improved disease-free survival and overall survival, however further research is needed.

According to Sacco, trials have not shown a survival benefit with induction chemotherapy, therefore the use of induction chemotherapy should be limited to select patients.

SELECTED
LANGUAGE


Assuntina G. Sacco, MD, assistant professor of medicine, medical oncologist, UC San Diego Health, discusses upfront treatment for patients with head and neck cancer.

Data suggests that higher-dose cisplatin is superior to weekly-dose regarding local regional control. There is a trend to improved disease-free survival and overall survival, however further research is needed.

According to Sacco, trials have not shown a survival benefit with induction chemotherapy, therefore the use of induction chemotherapy should be limited to select patients.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
Publication Bottom Border
Border Publication
x